(Q37816399)

23 August 2017

1 reference

title

Antifungal prophylaxis and therapy in patients with hematological malignancies and hematopoietic stem cell transplant recipients (English)

1 reference

stem cell transplantation

23 August 2017

main subject

1 reference

based on heuristic

inferred from title

author name string

Nikolaos G Almyroudis

series ordinal

1

1 reference

23 August 2017

Brahm H Segal

series ordinal

2

1 reference

23 August 2017

publication date

1 December 2010

1 reference

Expert Review of Anti-infective Therapy

23 August 2017

published in

1 reference

23 August 2017

volume

8

1 reference

23 August 2017

issue

12

1 reference

23 August 2017

page(s)

1451-1466

1 reference

Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997.

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Review of epidemiology, diagnosis, and treatment of invasive mould infections in allogeneic hematopoietic stem cell transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Stage-specific manifestation of mold infections in bone marrow transplant recipients: risk factors and clinical significance of positive concentrated smears.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Invasive mold infections in allogeneic bone marrow transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Fusarium infection in hematopoietic stem cell transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Infections due to emerging and uncommon medically important fungal pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Mortality and costs of acute renal failure associated with amphotericin B therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Correlates of acute renal failure in patients receiving parenteral amphotericin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Amphotericin B: time for a new "gold standard".

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Oral azole drugs as systemic antifungal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Mechanisms of fungal resistance: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Optimisation of itraconazole therapy using target drug concentrations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Congestive heart failure associated with itraconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Voriconazole therapeutic drug monitoring.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Photosensitivity in immunocompromised patients receiving long-term therapy with oral voriconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Characterization of Aspergillus fumigatus mutants with reduced susceptibility to caspofungin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Impact of pharmacodynamics and pharmacokinetics on echinocandin dosing strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Studies of the paradoxical effect of caspofungin at high drug concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. SCOPE Participant Group. Surveillance and Control of Pathog

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion test

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Comparison of caspofungin and amphotericin B for invasive candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Anidulafungin versus fluconazole for invasive candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Candida orthopsilosis and Candida metapsilosis spp. nov. to replace Candida parapsilosis groups II and III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Effects of caspofungin against Candida guilliermondii and Candida parapsilosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Adjuvant corticosteroid therapy for chronic disseminated candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Improved outcome in central nervous system aspergillosis, using voriconazole treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Amphotericin B lipid complex in the management of invasive aspergillosis in immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Study of renal safety in amphotericin B lipid complex-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Combination antifungal therapy for invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Epidemiology and outcome of zygomycosis: a review of 929 reported cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Posaconazole as salvage therapy for zygomycosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

The iron chelator deferasirox protects mice from mucormycosis through iron starvation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Fusarium infections in immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Voriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Posaconazole as Salvage Treatment for Invasive Fusariosis in Patients with Underlying Hematologic Malignancy and Other Conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Disseminated phaeohyphomycosis: review of an emerging mycosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Epidemiology and outcome of Scedosporium prolificans infection, a review of 162 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Primary central nervous system phaeohyphomycosis: a review of 101 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Non-comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Detection of circulating Aspergillus fumigatus DNA by real-time PCR assay of large serum volumes improves early diagnosis of invasive aspergillosis in high-risk adult patients under hematologic surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Value of serial quantification of fungal DNA by a real-time PCR-based technique for early diagnosis of invasive Aspergillosis in patients with febrile neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Characterization and comparison of galactomannan enzyme immunoassay and quantitative real-time PCR assay for detection of Aspergillus fumigatus in bronchoalveolar lavage fluid from experimental invasive pulmonary aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Genomic islands in the pathogenic filamentous fungus Aspergillus fumigatus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Harnessing calcineurin as a novel anti-infective agent against invasive fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Combination antifungals: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Immunotherapy for fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Pretreatment with empty liposomes attenuates the immunopathology of invasive pulmonary aspergillosis in corticosteroid-immunosuppressed mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting Toll-like receptor signalling from TLR-2 to TLR-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

A drug-sensitive genetic network masks fungi from the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Caspofungin modulates inflammatory responses to Aspergillus fumigatus through stage-specific effects on fungal beta-glucan exposure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Cryptococcosis in Australasia and the treatment of cryptococcal and other fungal infections with liposomal amphotericin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Immune reconstitution syndrome and exacerbation of infections after pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in AIDS patients with cryptococcal meningitis: a prospective multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Clearance of fungal burden during treatment of disseminated histoplasmosis with liposomal amphotericin B versus itraconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Antigen clearance during treatment of disseminated histoplasmosis with itraconazole versus fluconazole in patients with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Infectious Complications Associated with Alemtuzumab Use for Lymphoproliferative Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.141

21 January 2018

Identifiers

DOI

10.1586/ERI.10.141

1 reference

23 August 2017

1 reference